Send to

Choose Destination
AIDS Res Hum Retroviruses. 2019 Dec 4. doi: 10.1089/AID.2019.0175. [Epub ahead of print]

The Dose Response: Perceptions of People Living with HIV in the United States on Alternatives to Oral Daily Antiretroviral Therapy.

Author information

Public Health Leadership Program (PHLP), UNC Gillings School of Global Public Health, Chapel Hill, North Carolina.
Women's Research Initiative on HIV/AIDS (WRI), Chapel Hill, North Carolina.
Environmental Finance Center, UNC School of Government, Chapel Hill, North Carolina.
Delaney AIDS Research Enterprise (DARE) Community Advisory Board, Los Angeles, California.
Division of Prevention Sciences, Center for AIDS Prevention Studies (CAPS), University of California, San Francisco, San Francisco, California.
Department of Social Medicine, Population and Public Health, Center for Healthy Communities, University of California, Riverside School of Medicine, Riverside, California.
The Well Project, Norwich, Vermont.
The Well Project Community Advisory Board, Tamarac, Florida.
AIDS Clinical Trials Group (ACTG) Community Scientific Subcommittee Representative, Baltimore, Maryland.
UNC Department of Social Medicine, School of Medicine, Chapel Hill, North Carolina.
School of Medicine, University of California, San Francisco, San Francisco, California.
Institute of Global Health and Infectious Diseases (IGHID), University of North Carolina, Chapel Hill, North Carolina.


There are two concurrent and novel major research pathways toward strategies for HIV control: (1) long-acting antiretroviral therapy (ART) formulations and (2) research aimed at conferring sustained ART-free HIV remission, considered a step toward an HIV cure. The importance of perspectives from people living with HIV on the development of new modalities is high, but data are lacking. We administered an online survey in which respondents selected their likelihood of participation or nonparticipation in HIV cure/remission research based on potential risks and perceived benefits of these new modalities. We also tested the correlation between perceptions of potential risks and benefits with preferences of virologic control strategies and/or responses to scenario choices, while controlling for respondent characteristics. Of the 282 eligible respondents, 42% would be willing to switch from oral daily ART to long-acting ART injectables or implantables taken at 6-month intervals, and 24% to a hypothetical ART-free remission strategy. We found statistically significant gender differences in perceptions of risk and preferences of HIV control strategies, and possible psychosocial factors that could mediate willingness to switch to novel HIV treatment or remission options. Our study yielded data on possible desirable product characteristics for future HIV treatment and remission options. Findings also revealed differences in motivations and preferences across gender and other sociodemographic characteristics that may be actionable as part of research recruitment efforts. The diversity of participant perspectives reveals the need to provide a variety of therapeutic options to people living with HIV and to acknowledge their diverse experiential expertise when developing novel HIV therapies.


HIV cure research; HIV remission; United States; antiretroviral therapy (ART); long-acting ART; oral daily ART; people living with HIV


Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center